11月29日,南京维立志博生物科技股份有限公司(简称:维立志博),向港交所递交了IPO申请书。而此时,距这家创新药企业宣布旗下一款三抗产品Newco出海,还不足一个月。尽管目前国内融资环境已有回暖迹象,但资本寒冬仍在,因此不止一家投资机构的人士曾表示,在越来越内卷的创新药领域赛道,除了具备竞争优势的产品,能够有产品管线达成BD交易的企业,将更容易受到“金主”的青睐。而维立志博在旗下三抗产品顺利出海...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.